Procoagulant effect of vitamin K antagonists?

Strachan DP, Tang W, O Donnell CJ, Smith NL, de Maat MP. Effect of genetic variations in syntaxin-binding protein-5 and syntaxin-2 on von Willebrand factor concentration and cardiovascular risk. Circ Cardiovasc Genet 2010; 3: 507–12. 8 Eriksson N, Macpherson JM, Tung JY, Hon LS, Naughton B, Saxonov S, Avey L, Wojcicki A, Pe er I, Mountain J. Web-based, participant-driven studies yield novel genetic associations for common traits. PLoS Genet 2010; 6: e1000993. 9 Klinge U, Binnebosel M,Mertens PR. Are collagens the culprits in the development of incisional and inguinal hernia disease?Hernia 2006; 10: 472–7. 10 Liem EB, Lin CM, Suleman MI, Doufas AG, Gregg RG, Veauthier JM, Loyd G, Sessler DI. Anesthetic requirement is increased in redheads. Anesthesiology 2004; 101: 279–83.

[1]  C. Esmon,et al.  Isolation of a membrane-bound cofactor for thrombin-catalyzed activation of protein C. , 1982, The Journal of biological chemistry.

[2]  J. Deckers,et al.  Optimal intensity of oral anticoagulant therapy after myocardial infarction. , 1996, Journal of the American College of Cardiology.

[3]  F. Rosendaal,et al.  Risk of venous thromboembolism and clinical manifestations in carriers of antithrombin, protein C, protein S deficiency, or activated protein C resistance: a multicenter collaborative family study. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[4]  P. Mannucci,et al.  Risk of venous thromboembolism and clinical manifestations in carriers of antithrombin, protein C, protein S deficiency, or activated protein C resistance: a multicenter collaborative family study. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[5]  J. Vandenbroucke,et al.  Oral contraceptives and the risk of venous thrombosis. , 2001, The New England journal of medicine.

[6]  H. Coenraad Hemker,et al.  Calibrated Automated Thrombin Generation Measurement in Clotting Plasma , 2003, Pathophysiology of Haemostasis and Thrombosis.

[7]  J. Lassen,et al.  Is there a hypercoagulable phase during initiation of antithrombotic therapy with oral anticoagulants in patients with atrial fibrillation? , 2003, Thrombosis research.

[8]  A. Schafer.  Warfarin for venous thromboembolism - walking the dosing tightrope. , 2003, The New England journal of medicine.

[9]  J. Hirsh,et al.  The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. , 2004, Chest.

[10]  H. Hemker,et al.  Thrombin generation, a function test of the haemostaticthrombotic system , 2006, Thrombosis and Haemostasis.

[11]  F. Rosendaal,et al.  Different effects of oral contraceptives containing different progestogens on protein S and tissue factor pathway inhibitor , 2008, Journal of thrombosis and haemostasis : JTH.